TriGemX Bio
Biotech developing oral therapies for migraine
Community-submitted · content unverified. This organization has not verified ownership or the information in this profile.
About
TriGemX Bio (formerly Kallyope) is a New York City biotechnology company developing medicines for migraine. Its late-stage pipeline is led by elismetrep (K-304), an investigational oral TRPM8 channel blocker for the acute treatment of migraine that has entered Phase 3 development according to company announcements.
- Website
- trigemxbio.com
- Stage
- series-b+
- Location
- New York, USA
- Added via
- web
- Ownership
- unclaimed
Where to go
Products
- Elismetrep — Investigational oral TRPM8 blocker for acute migraine · Other